Literature DB >> 10196011

A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients.

A J Bleyer1, S K Burke, M Dillon, B Garrett, K S Kant, D Lynch, S N Rahman, P Schoenfeld, I Teitelbaum, S Zeig, E Slatopolsky.   

Abstract

Current phosphate binders used in hemodialysis patients include calcium-based binders that result in frequent hypercalcemia and aluminum-based binders that result in total body aluminum accumulation over time. This investigation describes the use of a calcium- and aluminum-free phosphate-binding polymer in hemodialysis patients and compares it with a standard calcium-based phosphate binder. An open-label, randomized, crossover study was performed to evaluate the safety and effectiveness of sevelamer hydrochloride in controlling hyperphosphatemia in hemodialysis patients. After a 2-week phosphate binder washout period, stable hemodialysis patients were administered either sevelamer or calcium acetate, and the dosages were titrated upward to achieve improved phosphate control over an 8-week period. After a 2-week washout period, patients crossed over to the alternate agent for 8 weeks. Eighty-four patients from eight centers participated in the study. There was a similar decrease in serum phosphate values over the course of the study with both sevelamer (-2.0 +/- 2.3 mg/dL) and calcium acetate (-2.1 +/- 1.9 mg/dL). Twenty-two percent of patients developed a serum calcium greater than 11.0 mg/dL while receiving calcium acetate, versus 5% of patients receiving sevelamer (P < 0.01). The incidence of hypercalcemia for sevelamer was not different from the incidence of hypercalcemia during the washout period. Patients treated with sevelamer also sustained a 24% mean decrease in serum low-density lipoprotein cholesterol levels. Sevelamer was effective in controlling hyperphosphatemia without resulting in an increase in the incidence of hypercalcemia seen with calcium acetate. This agent appears quite effective in the treatment of hyperphosphatemia in hemodialysis patients, and its usage may be advantageous in the treatment of dialysis patients.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10196011     DOI: 10.1016/s0272-6386(99)70221-0

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  43 in total

Review 1.  Hyperphosphataemia in renal failure: causes, consequences and current management.

Authors:  Fouad Albaaj; Alastair Hutchison
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  End stage renal disease.

Authors:  Yoshio N Hall; Glenn M Chertow
Journal:  BMJ Clin Evid       Date:  2007-10-17

3.  Prevalence and risk factors for hypercalcemia among non-dialysis patients with chronic kidney disease-mineral and bone disorder.

Authors:  Jun Jie Benjamin Seng; Ying Lin Cheryl Tan; Rou Wei Lim; Hui Ting Sarah Ng; Puay Hoon Lee; Jiunn Wong
Journal:  Int Urol Nephrol       Date:  2018-06-07       Impact factor: 2.370

4.  Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.

Authors:  Geoffrey A Block; David P Rosenbaum; Maria Leonsson-Zachrisson; Magnus Åstrand; Susanne Johansson; Mikael Knutsson; Anna Maria Langkilde; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2017-02-03       Impact factor: 10.121

5.  Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis.

Authors:  Markus Ketteler; Marianne Rix; Stanley Fan; Nicholas Pritchard; Ove Oestergaard; Scott Chasan-Taber; Jeremy Heaton; Ajay Duggal; Philip A Kalra
Journal:  Clin J Am Soc Nephrol       Date:  2008-05-01       Impact factor: 8.237

Review 6.  Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.

Authors:  Víctor Lorenzo Sellares; Armando Torres Ramírez
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

7.  A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis.

Authors:  Stanley Fan; Calum Ross; Sandip Mitra; Philip Kalra; Jeremy Heaton; John Hunter; Melissa Plone; Nick Pritchard
Journal:  Nephrol Dial Transplant       Date:  2009-08-07       Impact factor: 5.992

8.  The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol.

Authors:  David Pierce; Stuart Hossack; Lynne Poole; Antoine Robinson; Heather Van Heusen; Patrick Martin; Michael Smyth
Journal:  Nephrol Dial Transplant       Date:  2010-10-04       Impact factor: 5.992

9.  Dietary phosphorus reduction by pretreatment of human breast milk with sevelamer.

Authors:  Elizabeth Ferrara; Jacques Lemire; Vivian M Reznik; Paul C Grimm
Journal:  Pediatr Nephrol       Date:  2004-04-22       Impact factor: 3.714

10.  Phosphate binding therapy in dialysis patients: focus on lanthanum carbonate.

Authors:  Ismail A Mohammed; Alastair J Hutchison
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.